Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine

被引：6
|
作者：
Yamasaki, Satoshi [1 ,2 ]
Kohno, Kentaro [1 ,2 ]
Kadowaki, Masanori [1 ,2 ]
Takase, Ken [1 ,2 ]
Iwasaki, Hiromi [1 ,2 ]
机构：
[1] Natl Hosp Org Kyushu Med Ctr, Dept Hematol, Chuo Ku, 1-8-1 Jigyohama, Fukuoka 8108563, Japan
[2] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Chuo Ku, 1-8-1 Jigyohama, Fukuoka 8108563, Japan
来源：
ANNALS OF HEMATOLOGY | 2017年 / 96卷 / 07期
关键词：
REACTIVATION;
D O I：
10.1007/s00277-017-3005-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1215 / 1217
页数：3
相关论文
共 50 条
  • [21] Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma
    Kang, Hye Jin
    Lee, Seung-Sook
    Byun, Byung Hyun
    Kim, Kyeong Min
    Lim, Ilhan
    Choi, Chang Woon
    Suh, Cheolwon
    Kim, Won Seog
    Nam, Seung-Hyun
    Lee, Soon Il
    Eom, Hyeon Seok
    Shin, Dong-Yeop
    Lim, Sang Moo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 945 - 953
  • [22] Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma
    Hye Jin Kang
    Seung-Sook Lee
    Byung Hyun Byun
    Kyeong Min Kim
    Ilhan Lim
    Chang Woon Choi
    Cheolwon Suh
    Won Seog Kim
    Seung-Hyun Nam
    Soon Il Lee
    Hyeon Seok Eom
    Dong-Yeop Shin
    Sang Moo Lim
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 945 - 953
  • [23] Low-grade B cell lymphoma of the thymus
    Lorsbach, RB
    Shahsafaei, A
    Dorfman, DM
    LABORATORY INVESTIGATION, 1999, 79 (01) : 142A - 142A
  • [24] Efficacy of 90Y-ibritumomab tiuxetan treatment for relapsed and refractory low-grade B-cell and mantle cell lymphoma
    Motomura, Sayuri
    Suda, Atsuhiro
    Inoue, Misato
    Takashi, Yoshikawa
    Atsushi, Yamamoto
    Hiroko, Hidai
    Hisashi, Tsutsumi
    Junichi, Nagashima
    ANNALS OF ONCOLOGY, 2015, 26 : 109 - 109
  • [25] A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma
    Foss, Francine Marie
    Parker, Terri
    ONCOLOGIST, 2018, 23 (04): : 397 - +
  • [26] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Murayama, Kayoko
    Kiguchi, Toru
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Rai, Shinya
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Fukushima, Koji
    Terui, Yasuhito
    ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
  • [27] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
  • [28] A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-hodgkin lymphoma
    Larson, BJG
    Waples, JM
    Pusateri, A
    Mendenhall, NP
    Lynch, JW
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (02): : 165 - 168
  • [29] Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
    H Saito
    D Maruyama
    A M Maeshima
    S Makita
    H Kitahara
    K Miyamoto
    S Fukuhara
    W Munakata
    T Suzuki
    Y Kobayashi
    H Taniguchi
    K Tobinai
    Blood Cancer Journal, 2015, 5 : e362 - e362
  • [30] Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
    Saito, H.
    Maruyama, D.
    Maeshima, A. M.
    Makita, S.
    Kitahara, H.
    Miyamoto, K.
    Fukuhara, S.
    Munakata, W.
    Suzuki, T.
    Kobayashi, Y.
    Taniguchi, H.
    Tobinai, K.
    BLOOD CANCER JOURNAL, 2015, 5 : e362 - e362
12345